Indication: Breast Cancer

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Neoadjuvant Triple Negative Breast Cancer

Sub-indication: Newly diagnosed triple negative breast cancer

Line of Therapy: 1st line- newly diagnosed triple negative

Drug Study

Principal Investigator: Jeffrey Hargis, M.D.
Norton Cancer Institute

Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)

Learn more at ClinicalTrials.gov

Email for more information: Breast-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.